5-methylsulfanylmethyl-1H-pyrimidine-2,4-dione | 4874-40-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-methylsulfanylmethyl-1H-pyrimidine-2,4-dione
• 英文别名: 5-methylthiomethyluracil；5-Methylthiomethyl-uracil；5-(methylsulfanylmethyl)-1H-pyrimidine-2,4-dione
• CAS: 4874-40-2
• 化学式: C₆H₈N₂O₂S
• 分子量: 172.208
• InChiKey: YLMMYIIRADIZJQ-UHFFFAOYSA-N

物化性质

• 熔点：
  258-260 °C
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  83.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methylsulfanylmethyl-1H-pyrimidine-2,4-dione 在 ammonium sulfate 、 N-碘代丁二酰亚胺 、 三甲基氯硅烷 、 三氟甲磺酸三甲基硅酯 、 sodium methylate 、 六甲基二硅氮烷 作用下， 以 甲醇 为溶剂， 生成 1-((4S,5R)-4-Hydroxy-5-hydroxymethyl-tetrahydro-thiophen-2-yl)-5-methylsulfanylmethyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  Synthesis and Anti-Herpes Virus Activity of 2‘-Deoxy-4‘-thiopyrimidine Nucleosides

  摘要：

  A series of 5-substituted 2'-deoxy-4'-thiopyrimidine nucleosides was synthesized and evaluated as potential antiviral agents. A number of analogues such as 2'-deoxy-5-propyl-4'-thiouridine (3ii), 2'-deoxy-5-isopropyl-4'-thiouridine (3iii), 5-cyclopropyl-2'-deoxy-4'-thiouridine (3iv), 2'-deoxy-4'-thio-5-vinyluridine (3viii), and 5-(2-chloroethyl)-2'-deoxy-4'-thiouridin (3xx) were found to be highly active against herpes simplex virus type-1 (HSV-1) and varicella tester virus (VZV) in vitro with no significant cytotoxicity. The compound with the broadest spectrum of activity was 2'-deoxy-5-ethyl-4'-thiouridine (3i) which showed significant activity against HSV-1, HSV-2, and VZV.

  DOI：

  10.1021/jm950029r
• 作为产物：
  描述：

  5-羟甲基脲嘧啶 在 氯化亚砜 作用下， 以 1,4-二氧六环 、 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 5-methylsulfanylmethyl-1H-pyrimidine-2,4-dione
  参考文献：
  名称：

  DIAZEPINO-THIENO-QUINOXALINE COMPOUNDS AND THEIR USE IN THERAPY

  摘要：

  The invention provides diazepino-thieno-quinoxaline compounds, pharmaceutical compositions, their use for inhibiting MK2, and their use in the treatment of a disease or condition, such as an inflammatory disorder.

  公开号：

  WO2024044731A1

文献信息

• 2-(3-Amino-2-hydroxy-propoxy)-pyrazines
  申请人：Ciba-Geigy Corporation

  公开号：US04115575A1

  公开（公告）日：1978-09-19

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alkyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-rezeptor blocking agents, and/or (cardioselective) .beta.-rezeptor-stimulants.

  该公式表示的杂环化合物，其中Het表示可选择替代的吡啶啉基、嘧啶基、吡嗪基或取代的吡啶基，R.sub.1是氢或甲基，R.sub.2是较低的烷基，可选择取代的苯基-较低的烷基，羧基-较低的烷基或功能修饰的羧基-较低的烷基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物，这些化合物是有价值的（心脏选择性）β-受体阻滞剂和/或（心脏选择性）β-受体激动剂。
• 2-(3-Amino-2-hydroxy-propoxy)-mono-and diazines
  申请人：Ciba-Geigy Corporation

  公开号：US04410530A1

  公开（公告）日：1983-10-18

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alklyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-receptor blocking agents, and/or (cardioselective) .beta.-receptor-stimulants.

  式为##STR1##的杂环化合物，其中Het表示可选择地取代的吡啶啉基、嘧啶基、吡嗪基或取代的吡啶基，R.sub.1为氢或甲基，R.sub.2为低碳链基、可选择地取代的苯基-低碳链基、羧基-低碳链基或功能性改性的羧基-低碳链基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物，是有价值的（心脏选择性的）β-受体阻滞剂和/或（心脏选择性的）β-受体激动剂。
• 2-(3-Amino-2-hydroxy-propoxy)pyridine derivatives and pharmaceutical
  申请人：Ciba-Geigy Corporation

  公开号：US04195090A1

  公开（公告）日：1980-03-25

  Heterocyclic compounds of the formula ##STR1## wherein Het denotes optionally substituted pyridazinyl, pyrimidinyl, pyrazinyl or substituted pyridyl, R.sub.1 is hydrogen or methyl and R.sub.2 is lower alkyl, optionally substituted phenyl-lower alkyl, carboxy-lower alkyl or functionally modified carboxy-lower alkyl, their condensation products with aldehydes, ketones or carbonic acid and their N-oxides, which are valuable (cardioselective) .beta.-rezeptor blocking agents, and/or (cardioselective) .beta.-rezeptor-stimulants.

  式中，Het表示可选取代的吡啶并嗪基、嘧啶基、吡嗪基或取代的吡啶基，R.sub.1为氢或甲基，R.sub.2为低碳基、可选取代的苯基-低碳基、羧基-低碳基或功能修饰的羧基-低碳基，它们与醛、酮或碳酸的缩合产物以及它们的N-氧化物是有价值的（心脏选择性）β-受体阻滞剂和/或（心脏选择性）β-受体激动剂。
• Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
  申请人：Queen's University

  公开号：US20030153584A1

  公开（公告）日：2003-08-14

  Methods and compounds useful for the inhibition of convulsive disorders, including epilepsy, are disclosed. The methods and compounds of the invention inhibit or prevent ictogenesis and/or epileptogenesis. Methods for preparing the compounds of the invention are also described. Particularly preferred compounds of the invention include: 1

  本发明揭示了用于抑制惊厥性疾病，包括癫痫的方法和化合物。本发明的方法和化合物能够抑制或预防发作和/或癫痫发生。本发明还描述了制备本发明化合物的方法。本发明特别优选的化合物包括：1
• EP1385831A2
  申请人：——

  公开号：EP1385831A2

  公开（公告）日：2004-02-04